[Antifibrinolytic treatment after subarachnoid hemorrhage].
The value of the antifibrinolytic treatment was assessed in two groups od patients treated after subarachnoid haemorrhage from ruptured aneurysm. One group of 449 patients received EACA before the operation, and 308 were not given EACA. The effectiveness of this treatment was analysed considering the frequency of recurrent haemorrhages, site of aneurysm and sequelae of recurrent haemorrhage as well as ischaemic complications of subarachnoid haemorrhage. The frequency of recurrent haemorrhages was significantly lower in the group not treated with EACA, and the frequency of ischaemic complications of subarachnoid haemorrhage was significantly higher in those treated with EACA.
Marchel
A
A
Kliniki Neurochirurgii Instytutu Chirurgii AM, Warszawie.
D015119:Aminocaproic Acid / Q000627:therapeutic use*; D017542:Aneurysm, Ruptured / Q000150:complications*; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications*; D012008:Recurrence; D012422:Rupture, Spontaneous; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D015119:Aminocaproic Acid
Leczenie antyfibrynolityczne po krwotoku podpajeczynówkowym.